Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Denize

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Histopathology|March 3, 2022
Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 casesThomas Denize, Simona Massa, Alexander Valent, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Annales De Pathologie|February 4, 2019
[Large scale teaching in pathology]Philippe Bertheau, Thomas Denize, Julien Calvani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Nature Communications|August 25, 2022
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1Hsiao-Yun Chen, Yavuz T Durmaz, Yixiang Li, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma PatientsThomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Histopathology|March 3, 2022
Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 casesThomas Denize, Simona Massa, Alexander Valent, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Annales De Pathologie|February 4, 2019
[Large scale teaching in pathology]Philippe Bertheau, Thomas Denize, Julien Calvani, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Nature Communications|August 25, 2022
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1Hsiao-Yun Chen, Yavuz T Durmaz, Yixiang Li, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma PatientsThomas Denize, Opeyemi A Jegede, Sayed Matar, et al.
Pageof 5